Researchers say cediranib has “tolerable toxicity” and “promising efficacy” within the treatment of malignant mesothelioma.
Raleigh, NC (PRWEB) June 18, 2017
A brand new medical trial of the VEGF-inhibitor cediranib means that, on the proper dose, the drug may safely be used to enhance the effectiveness of ordinary chemotherapy for pleural mesothelioma. Surviving Mesothelioma has revealed a brand new article on the trial. Click here to read it now.
For the Phase I trial, docs at a number of US cancer facilities helped check a mesothelioma treatment mixture together with the oral cancer drug cediranib the the usual mesothelioma chemotherapy medicine pemetrexed (Alimta) and cisplatin.
“Cediranib combined with cisplatin-pemetrexed has a reasonable toxicity profile and preliminary promising efficacy,” writes oncologist Anne Tsao, MD, of MD Anderson Cancer Center in Texas.
The research, revealed within the Journal of Thoracic Oncology, decided that 20 milligrams of cediranib, taken throughout every chemotherapy cycle for six cycles, produced a illness management fee of 90 % and a median general survival of 16.2 months.
“Although previous studies of cediranib have produced some severe side effects, this study of the drug at a smaller dose suggests that it may still have a role to play in mesothelioma treatment,” says Alex Strauss, Managing Editor for Surviving Mesothelioma.
For the entire particulars of the brand new cediranib research, in addition to background on the drug, see Cediranib May be Safe Supplement to Mesothelioma Treatment, now obtainable on the Surviving Mesothelioma web site.
Tsao, AS, et al, “Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905)”, June 6, 2017, Journal of Thoracic Oncology, Epub forward of print, http://www.sciencedirect.com/science/article/pii/S155608641730429X
For greater than a decade, Surviving Mesothelioma has introduced readers crucial and floor-breaking information on the causes, analysis and treatment of mesothelioma. All Surviving Mesothelioma information is gathered and reported instantly from the peer-reviewed medical literature. Written for sufferers and their family members, Surviving Mesothelioma information helps households make extra knowledgeable selections.
For the unique model on PRWeb go to: http://www.prweb.com/releases/2017/06/prweb14436904.htm